Meta-analysis · people

Thymosin Alpha-1 vs interferon in hepatitis B: better at follow-up

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

In chronic hepatitis B, thymosin alpha-1 did no better than interferon alpha by the end of treatment but outperformed it 6 months later, mainly in HBeAg-negative patients.

Kind
Meta-analysis
Studied in
People
Number studied
199
Published
2008
Journal
Antiviral Res

What they tested

The team asked whether thymosin alpha-1 works better or worse than interferon alpha for treating chronic hepatitis B.

How the study was done

A meta-analysis, which pools results from several studies, of randomized controlled trials with 199 people with chronic hepatitis B who got either thymosin alpha-1 or interferon alpha. Results were checked at the end of 6 months of treatment and again 6 months after treatment stopped.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Thymosin Alpha-1? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Results are given as odds ratios (OR), where a number above 1 favors thymosin alpha-1 and below 1 favors interferon alpha. At the end of 6 months of treatment, the ORs for thymosin alpha-1 were 0.62 (95% CI 0.35, 1.10) for viral response and 0.60 (0.34, 1.05) for liver enzyme response, so neither showed a clear difference, while complete response, meaning both at once, was 0.54 (0.30, 0.97), favoring interferon. Six months after treatment ended, the ORs flipped in favor of thymosin alpha-1: 3.71 (2.05, 6.71) for viral response, 3.12 (1.74, 5.62) for liver enzyme response and 2.69 (1.47, 4.91) for complete response. The authors say responses to thymosin alpha-1 seemed to build up gradually after therapy ended.

What it doesn’t show

It pools only a handful of small trials, and most of them studied HBeAg-negative patients (people whose blood lacks the hepatitis B e antigen marker), so the results mainly apply to that group. Follow-up lasted only 6 months after treatment.

The paper

Yang et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res. 2008.

The compound

More studies on Thymosin Alpha-1

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Thymosin Alpha-1? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo